Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
This pooled analysis of seven multi-ethnic cohorts demonstrates the combined prognostic value of plasma phosphorylated tau 217 concentrations and APOE-ε4 genotype for predicting risk and timing of cognitive impairment, emphasizing biomarker
Longitudinal analysis of blood proteins reveals distinctive trajectories and associations with cognitive decline in adults with Down syndrome, shedding light on Alzheimer’s disease pathophysiology in this high-risk group.
A multiprotein plasma panel improves detection of advanced neocortical tau pathology in Alzheimer’s disease risk individuals beyond p-tau217 alone, enhancing patient stratification and clinical trial selection.
This review synthesizes evidence linking NOAC use to slower cognitive decline and improved clinical outcomes in patients with atrial fibrillation and Alzheimer’s disease, highlighting advantages over warfarin and non-use.
Plasma phosphorylated tau biomarkers overlap in Alzheimer’s and prion diseases, risking diagnostic confusion. The NfL/p-tau217 ratio emerges as an accurate plasma biomarker to distinguish prion diseases from Alzheimer’s, improving diagnosti
This review examines the impact of traumatic brain injury on the accuracy of Alzheimer disease blood biomarkers, highlighting reduced diagnostic performance in TBI-affected populations and the implications for clinical interpretation.
Higher parity in cognitively unimpaired postmenopausal women with positive β-amyloid status is linked to accelerated cognitive decline and hippocampal volume reduction, suggesting parity modulates resilience to Alzheimer’s pathology in prec
A genome-wide study identified three genetic modifiers of autosomal dominant Alzheimer’s disease, linking them to disease risk, earlier onset, and biomarker changes involving amyloid, tau, TDP-43, and brain aging.
Women with high amyloid-β show higher p-tau217 levels and faster tau accumulation than men, leading to greater cognitive decline. This sex-specific tau response may redefine preclinical Alzheimer’s diagnostics and therapeutics.
Women exhibit higher plasma p-tau217 levels and tau aggregation than men in amyloid-positive individuals, suggesting sex-specific pathways in Alzheimer’s disease progression.
This review synthesizes recent clinical evidence on the integration of plasma p-tau217 and eMTBR-tau243, highlighting how sequential biomarker testing improves the diagnosis of symptomatic Alzheimer’s disease and predicts longitudinal cogni
A large-scale analysis of the VA Million Veteran Program reveals that TBI, depression, and specific military environmental exposures significantly elevate the 10-year risk of Alzheimer’s and related dementias, highlighting critical targets
This review synthesizes evidence on the impact of kidney function, BMI, and anemia on plasma p-tau217 diagnostic accuracy, advocating for subgroup-specific cutoff strategies to improve clinical outcomes.
This study highlights how comorbid Alzheimer’s and FTLD neuropathologies manifest through unique neuropsychiatric profiles, such as increased anxiety and personality changes, providing clinicians with vital clues for identifying mixed
This pilot randomized clinical trial investigated low-dose lithium for Mild Cognitive Impairment (MCI). While primary outcomes regarding cognition and neuroimaging were not statistically significant, the study established the intervention&#
A multi-cohort study demonstrates that women with amyloid-β pathology show higher plasma p-tau217 levels and faster tau PET accumulation than men, providing a biological basis for their increased risk of rapid cognitive decline in preclinic
A large-scale longitudinal study reveals that over 80% of community-dwelling older adults harbor mixed neuropathologies, identifying five distinct profiles that dictate specific cognitive decline trajectories, with ADNC and LATE-NC clusters
Standard single cutoffs for plasma p-tau217 are significantly confounded by kidney function, BMI, and anemia. A new study demonstrates that subgroup-specific or double-cutoff strategies markedly improve diagnostic accuracy and cost-effectiv
The Phase 2b ELAD trial investigated liraglutide’s efficacy in mild-to-moderate Alzheimer’s disease. While it failed its primary metabolic endpoint, significant improvements in executive function suggest a nuanced role for GLP-1
Recent clinical evidence reveals that soluble amyloid-beta oligomers, rather than traditional plaques, drive glucose dysregulation and depression in early Alzheimer’s disease. Crucially, these associations are modulated by tau pathology, su